Oncolytics Biotech Q2 EPS $(0.13) Up From $(0.17) YoY

Oncolytics Biotech (NASDAQ:ONCY) reported quarterly losses of $(0.13) per share. This is a 23.53 percent increase over losses of $(0.17) per share from the same period last year.

byBenzinga Newsdesk

August 6, 2021

1 minute read

Oncolytics Biotech (NASDAQ:ONCY) reported quarterly losses of $(0.13) per share. This is a 23.53 percent increase over losses of $(0.17) per share from the same period last year.

SVB Leerink Maintains Outperform on Pliant Therapeutics, Raises Price Target to $45

By Benzinga Newsdesk

Today, 5:06 PM

SVB Leerink analyst Mike Kratky maintains Pliant Therapeutics (NASDAQ:PLRX) with a Outperform and raises the price target from $33 to $45.

PLRX

Bitcoin, Ethereum, Dogecoin Tumble: Analyst Sees Another Bear Rally As FTX Fallout Continues To Roil Crypto Market

By Mehab Qureshi

Today, 5:06 PM

The two largest cryptocurrencies, Bitcoin (CRYPTO: BTC) and Ethereum (CRYPTO: ETH), traded in the red on Sunday evening as the global cryptocurrency market cap shrunk 3.81% to $804.37 billion at 8:54 p.m. EST.

$DOGE

Rubius Therapeutics Reports Preclinical Data For RTX-224 Will Be Presented At Society For Immunotherapy Of Cancer Meeting Nov. 12 At 7 a.m. EST

By Benzinga Newsdesk

Today, 5:06 PM

Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell

RUBY